Advertisement

Topics

Clinical Trials About "Lambert Surhone Qiagen Kartoniert Broschiert" RSS

23:17 EST 24th November 2017 | BioPortfolio

We list hundreds of Clinical Trials about "Lambert Surhone Qiagen Kartoniert Broschiert" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Lambert Surhone Qiagen Kartoniert Broschiert" on BioPortfolio

We have published hundreds of Lambert Surhone Qiagen Kartoniert Broschiert news stories on BioPortfolio along with dozens of Lambert Surhone Qiagen Kartoniert Broschiert Clinical Trials and PubMed Articles about Lambert Surhone Qiagen Kartoniert Broschiert for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lambert Surhone Qiagen Kartoniert Broschiert Companies in our database. You can also find out about relevant Lambert Surhone Qiagen Kartoniert Broschiert Drugs and Medications on this site too.

Showing "Lambert Surhone Qiagen Kartoniert Broschiert" Clinical Trials, all 13

Relevant

Use of 3, 4-Diaminopyridine in Lambert Eaton Myasthenic Syndrome

Compassionate use of orphan drug 3,4-Diaminopyridine (DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). The purpose of the use of this drug is to decrease the weakness associated with Lambert -Eaton Myasthenic Syndrome, and hopefully decrease the need for prednisone, and other therapies previously required to control your symptoms. The duration of the use of this drug will depend upon whether you see benefit from it, and whether any side effects from the drug pre...


Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).


Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS)

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS).

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

A new drug called 3,4-Diaminopyridine (3,4-DAP) is currently under investigation for treatment of the symptoms of Lambert-Eaton Myasthenic Syndrome. This is an expanded access trial, which means that although data from this study will be collected and reported to the US Food and Drug Administration (FDA)and the drug manufacturer, this is not a formal study of drug in Lambert-Eaton Syndrome. If you decide to volunteer, you will be evaluated by a neurologist to determine your ...

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome

Congenital myasthenia and LEMS are potentially lethal disorder, which, even with careful management, significantly impedes participation in normal daily functions. Currently approved therapies have had little impact on promoting a normal quality of life activity in these patients. Our hope is to systematically examine the effect of 3,4-DAP on the natural course of this disease and to gain additional experience in titrating 3,4-DAP with other available therapies to maximize clin...

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

To assess and compare the performance of the HR HPV HC2® test (Qiagen/Digene) and the APTIMA® HPV Assay (Hologic) using LBC Specimens (ThinPrep® Pap Test) for the detection of HPV infection and high-grade CIN lesions in a screening population of women 30 years of age or older in Germany.

Probably Relevant

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.

Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions

Compare bioavailability of Pseudoephedrine hydrochloride extended release tablets (Ranbaxy Laboratories Limited) against reference product Sudafed ® 12-hour tablets 120 mg (Warner-Lambert) under fasting conditions.

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions

This study compared the relative bioavailability (rate and extent of absorption) of the test Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of Warner-Lambert Co. in 28 healthy, adult subjects (21 males and 7 females) under fasting conditions using randomized, two-way crossover design.

Candidate Gene Screening for Attention Deficit/Hyperactive Disorder (ADHD)

Source: Sample bank of Xijing Hospital and Children's Hospital Affiliated to Soochow University; Sample form: Whole blood; Estimated number of samples: 100 patients with ADHD and age, sex matched healthy controls; Case exclusion criteria: all kinds of neuropsychiatric disorders, IQ value of less than 70; Study protocol: 1. Using Qiagen kit to extract the genomic DNA of 200 microliters of blood. 2. UV spectrophotometer test DNA purity of 260/280 close to 1.8 (1.8 ±...

GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps

Colorectal cancer ist the 2nd most leading cancer among men and women in germany. Screening colonoscopy has the potential to detect premalignant lesions. By endoscopical resection of these lesions, colorectal cancers could be avoided. The decision for surveillance is made according to patients medical history, amount and histological characteristics of the resected polyps. Molecular guided decisions are still missing. Thus, further tools and mechanisms, beyond but in addition t...


More From BioPortfolio on "Lambert Surhone Qiagen Kartoniert Broschiert"

Quick Search
Advertisement